@article{19d7099ae80648b7aec2ebbeb3be514f,
title = "Complementary combinations: What treatments will become key to the battle against acute myelogenous leukemia?",
keywords = "AML, BH3-mimetics, CDK inhibitors, Chk1 inhibitors, FLT3 inhibitors, HDAC inhibitors, MEK inhibitors, Mcl-1, proteasome inhibitors, targeted therapies",
author = "Prithviraj Bose and Steven Grant",
note = "Funding Information: This work was supported by the following grants from the NIH: CA93738, CA100866, CA148431, CA137823, CA142509, and CA130805, and an award from the Leukemia and Lymphoma Society of America. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.",
year = "2012",
month = oct,
doi = "10.1586/ehm.12.43",
language = "English (US)",
volume = "5",
pages = "475--478",
journal = "Expert review of hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "5",
}